Cardiol Therapeutics
Stock Forecast, Prediction & Price Target
Cardiol Therapeutics Financial Estimates
Cardiol Therapeutics Revenue Estimates
Cardiol Therapeutics EBITDA Estimates
Cardiol Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $78.76K N/A | $0 -100% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $4.90M Low: $4.90M High: $4.90M avg. 0% | Avg: $49.13M Low: $49.13M High: $49.13M avg. 901.62% | Avg: $131.22M Low: $131.22M High: $131.22M avg. 167.05% |
Net Income
% change YoY
| $-31.63M N/A | $-30.93M 2.23% | $-28.12M 9.06% | Avg: $-45.33M Low: $-42.86M High: $-22.74M avg. -61.17% | Avg: $-48.05M Low: $-46.36M High: $-26.24M avg. -5.99% | Avg: $3.07M Low: $3.07M High: $3.07M avg. 106.39% | Avg: $39.56M Low: $39.56M High: $39.56M avg. 1187.88% |
EBITDA
% change YoY
| $-45.25M N/A | $-50.11M -10.75% | $-29.59M 40.96% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $2.94M Low: $2.94M High: $2.94M avg. 0% | Avg: $29.48M Low: $29.48M High: $29.48M avg. 901.62% | Avg: $78.73M Low: $78.73M High: $78.73M avg. 167.05% |
EPS
% change YoY
| -$0.73 N/A | -$0.49 32.87% | -$0.44 10.20% | Avg: -$0.57 Low: -$0.66 High: -$0.35 avg. -30.30% | Avg: -$0.56 Low: -$0.72 High: -$0.41 avg. 1.77% | Avg: $0.05 Low: $0.05 High: $0.05 avg. 108.46% | Avg: $0.61 Low: $0.61 High: $0.61 avg. 1187.88% |
Operating Expenses
% change YoY
| $38.74M N/A | $41.33M 6.69% | $29.78M -27.94% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $351.13M Low: $351.13M High: $351.13M avg. 0% | Avg: $3.51B Low: $3.51B High: $3.51B avg. 901.62% | Avg: $9.39B Low: $9.39B High: $9.39B avg. 167.05% |
FAQ
What is Cardiol Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 306.77% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -42.86M, average is -45.33M and high is -22.74M.
What is Cardiol Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 267.17% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Cardiol Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 316.95% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$0.66, average is -$0.57 and high is $-0.35.
What is the best performing analyst?
In the last twelve months analysts have been covering Cardiol Therapeutics stock. The most successful analyst is Edward Nash.